News

Aug 15, 2023

Biogen board, C

By Allison DeAngelis June 6, 2023 BOSTON — As Biogen’s new CEO Chris Viehbacher

By Allison DeAngelis June 6, 2023

BOSTON — As Biogen's new CEO Chris Viehbacher pores over Biogen's books and scouts out M&A deals, he may have one advantage his predecessor didn't: a good relationship with his board of directors.

Investors have expressed hope over the last several years that Biogen would make more acquisition deals, but it's been a point of contention within the company. Biogen's last chief executive, Michel Vounatsos, and his business development team put together proposals for several deals, but were often stymied by dueling factions on the board of directors, STAT reported last year.

advertisement

But Viehbacher has inherited a different board: In March, the company announced that Caroline Dorsa would take over as board chair from Stelios Papadopoulos.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Biotech Startups and Venture Capital Reporter

Allison DeAngelis is a biotech reporter at STAT, covering biopharma startups and venture capital.

BIO23

biotechnology

pharmaceuticals

STAT+

This name will appear with your comment

There was an error saving your display name. Please check and try again.